A5102991581- Particle accelerators and beam dynamics
- Lymphoma Diagnosis and Treatment
- Plasma Diagnostics and Applications
- Particle Accelerators and Free-Electron Lasers
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Muon and positron interactions and applications
- Nuclear Physics and Applications
- Magnetic confinement fusion research
- Gyrotron and Vacuum Electronics Research
- Viral-associated cancers and disorders
- Superconducting Materials and Applications
- Retinoids in leukemia and cellular processes
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Atomic and Molecular Physics
- X-ray Spectroscopy and Fluorescence Analysis
- Cutaneous lymphoproliferative disorders research
- Lung Cancer Treatments and Mutations
- Acute Lymphoblastic Leukemia research
- Glioma Diagnosis and Treatment
- Ion-surface interactions and analysis
- Mass Spectrometry Techniques and Applications
- Cancer Treatment and Pharmacology
- Electron and X-Ray Spectroscopy Techniques
Centre Hospitalier Universitaire de Rennes
2013-2024
Hôpital Pontchaillou
2010-2024
Inserm
2010-2024
Université Rennes 2
2024
Université de Rennes
2007-2024
Établissement Français du Sang
2024
Université Grenoble Alpes
2011-2022
Centre National de la Recherche Scientifique
2011-2022
Institut National de Physique Nucléaire et de Physique des Particules
2011-2022
CIC Rennes
2016-2022
Mantle-cell lymphoma is generally incurable. Despite high rates of complete response after initial immunochemotherapy followed by autologous stem-cell transplantation, patients have relapses. We investigated whether rituximab maintenance therapy at a dose 375 mg per square meter body-surface area administered every 2 months for 3 years transplantation would prolong the duration response.
To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy autologous stem-cell transplantation (ASCT) as a first-line treatment primary CNS lymphoma (PCNSL).Immunocompetent patients (18 to 60 years age) with untreated PCNSL were randomly assigned receive WBRT ASCT consolidation after induction consisting two cycles R-MBVP (rituximab 375 mg/m2 day (D) 1, methotrexate 3 g/m2 D1; D15, VP16 100 D2, BCNU D3,...
Real-life studies on patients with primary CNS lymphoma (PCNSL) are scarce. Our objective was to analyze, in a nationwide population-based study, the current medical practice management of PCNSL.The French oculo-cerebral network (LOC) database prospectively records all newly diagnosed PCNSL cases from 32 centers. Data between 2011 and 2016 were retrospectively analyzed.We identified 1,002 immunocompetent (43% aged >70 years, median Karnofsky Performance Status [KPS] 60). First-line treatment...
Treatment of relapsed/refractory (R/R) primary CNS lymphoma (PCNSL) is poorly defined, because randomized trials and large studies are lacking. The aim this study was to analyze the characteristics, management, outcome R/R PCNSL patients after first-line therapy in a nationwide cohort.We analyzed following treatment who had been prospectively registered database French network for oculocerebral (LOC) between 2011 2014.Among 563 treated with therapy, we identified 256 relapsed (n = 93, 16.5%)...
Large granular lymphocyte leukemia is a rare lymphoproliferative disorder associated with autoimmune diseases and impaired hematopoiesis. This study describes the clinical biological characteristics of 229 patients T-cell or NK-cell large leukemia.The diagnosis was based on expansion (> 0.5x10(9)/L) lasting more than 6 months. Monoclonal receptor gamma gene rearrangement detected in all cases leukemia. Patients chronic lymphocytosis had an indolent disease, while those multiorgan...
We present the case for a dark matter detector with directional sensitivity. This document was developed at 2009 CYGNUS workshop on detection, and contains contributions from theorists experimental groups in field. describe need sensitivity; each experiment presents their project's status; we close feasibility study scaling up to one ton detector, which would cost around $150M.
The utility of [(18)F]fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in assessing response at the end induction therapy is well documented Hodgkin's and diffuse large B-cell lymphomas, but its role follicular lymphoma (FL) remains undetermined. We investigated prognostic significance PET-CT performed after first-line patients with FL treated prospective Primary Rituximab Maintenance (PRIMA) study.Results scans immunochemotherapy were recorded...
Several phase II studies have suggested that cytarabine (AraC) was not required in the treatment of newly diagnosed acute promyelocytic leukemia (APL) patients receiving all-trans-retinoic acid (ATRA), an anthracycline, and maintenance therapy, we aimed at confirming this finding a randomized trial.Newly APL younger than age 60 years with WBC count less 10,000/microL were randomly assigned to receive either ATRA combined followed by three daunorubicin (DNR) plus AraC courses 2-year regimen...
Summary Peripheral T‐Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission survival rates than B‐cell lymphomas. Despite unsatisfactory results with the cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) regimen, it remains reference front‐line therapy in these diseases, has not been challenged phase III trials. The Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang (GOELAMS) devised an alternative...
To determine the efficacy and safety of bendamustine as a single agent in refractory or relapsed T-cell lymphomas.Patients with histologically confirmed peripheral lymphoma (PTCL) cutaneous who progressed after one more lines prior chemotherapy received at 120 mg/m(2) per day on days 1 through 2 every 3 weeks for six cycles. The primary end point was overall response rate (ORR). Secondary points were duration (DOR), progression-free survival (PFS), (OS).Of 60 patients included, 27 (45%) to...
The phase II part of the I/II GAUGUIN study evaluated efficacy and safety two different doses obinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, in patients with relapsed/refractory indolent non-Hodgkin lymphoma.Patients were randomly assigned to receive eight cycles (GA101) as flat dose 400 mg on days 1 8 cycle also day 2 (400/400 mg) or 1,600 800 (1,600/800 mg).Forty enrolled, including 34 follicular lymphoma; 38 40 had previously received rituximab...
<h3>Importance</h3> Cast nephropathy is the main cause of acute kidney injury in multiple myeloma and persistent reduction function strongly affects prognosis. Strategies to rapidly remove nephrotoxic serum-free light chains combined with novel antimyeloma agents have not been evaluated prospectively. <h3>Objective</h3> To compare hemodialysis independence rate among patients newly diagnosed cast treated using a high-cutoff dialyzer (with very large membrane pores high permeability...
The human germinal center is a highly dynamic structure where B cells conduct their terminal differentiation and traffic following chemokine gradients. rapidly dividing centroblasts the nondividing centrocytes represent two major cell subsets present in also most common normal counterparts for majority of lymphomas. CD77 expression was previously associated to proliferating undergoing somatic hypermutation, but data from transcriptional studies demonstrate that not reliable marker...
Purpose Acute promyelocytic leukemia (APL) with pretreatment WBC counts greater than 10,000/μL is still considered to carry a poorer prognosis APL lower 10,000/mL. We evaluated outcome improvement in such patients recent years. Patients and Methods Nine hundred two APL, including 204 68 more 50,000/μL, respectively, were enrolled between 1993 2005 successive randomized trials of the European group (APL 93 2000) that tested, particular, modalities combination all-trans retinoic acid (ATRA)...
The clinical course of polycythemia vera and essential thrombocythemia is potentially associated with long-term severe complications, such as evolution to myelofibrosis or acute myeloid leukemia. Allogeneic stem cell transplantation currently the only curative treatment for advanced thrombocythemia. We analyzed 250 consecutive patients an initial diagnosis (n=120) (n=130), who underwent due progression (n=193) leukemia (n=57) were reported European Group Blood Marrow Transplantation registry...
Tailoring treatment by patient strata based on the risk of disease progression and toxicity might improve outcomes patients with posttransplant lymphoproliferative disorder (PTLD). We analysed cohort 70 treated in international, multicenter phase II PTLD-1 trial (NCT01458548) to identify such factors. Of previously published scoring systems PTLD, international prognostic index (IPI), PTLD Ghobrial score were predictive for overall survival. None had a considerable effect progression. Age...